CDK4 and breast cancer: Overall, we demonstrate how ErbB2 receptor levels modulate the roles of cyclin D1 and c-Myc in the G1/S transition and suggest that variations in ErbB2 levels within breast cancer tissues confer heterogeneous sensitivity to CDK4 inhibitors, potentially complicating treatment.